0000000001139591

AUTHOR

Giovan Giuseppe Di Costanzo

showing 6 related works from this author

Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey

2014

BackgroundBone is an uncommon site of metastasis in patients with advanced hepatocellular carcinoma (HCC). Therefore, there are few studies concerning the natural history of bone metastasis in patients with HCC.Patients and methodsData on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 211 deceased HCC patients with evidence of bone metastasis were statistically analyzed.ResultsThe median age was 70 years; 172 patients were male (81.5%). The median overall survival was 19 months. The median time to the onset of bone metastasis was 13 months (22.2% at HCC diagnosis); 64.9% patients had multiple bone metastases. Spine was the most common site of bon…

MaleGenetics and Molecular Biology (all)medicine.medical_specialtyCarcinoma HepatocellularBone diseaseSettore MED/06 - Oncologia Medicamedicine.medical_treatmentScienceBone NeoplasmsGastroenterology and HepatologyBiochemistryGastroenterologyBone and BonesMetastasisInternal medicineMedicine and Health SciencesmedicineCarcinomaHumansAged; Bone Neoplasms; Bone and Bones; Carcinoma Hepatocellular; Female; Humans; Italy; Liver; Liver Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Survival analysisAgedPharmacologyMultidisciplinarybusiness.industryCarcinomaLiver NeoplasmsQRBone metastasisHepatocellularBone fractureMiddle AgedBisphosphonatemedicine.diseaseSurvival Analysiszoledronic acidHepatocellular Carcinomaskeletal-related eventsSurgeryZoledronic acidOncologyItalyLiverAgricultural and Biological Sciences (all)Quality of LifeMedicineFemalebusinessResearch Articlemedicine.drug
researchProduct

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

2021

[Background & Aims] The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.

Hepatocellular carcinomaLCmedicine.medical_treatment:diagnóstico::toma de decisiones clínicas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]NursesRC799-869Liver transplantationCholangiocarcinomaClinical trialsENS-CCAInterquartile rangeDecisió Presa dePandemic:Other subheadings::/diagnosis [Other subheadings]:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]CERO-19Pandèmia de COVID-19 2020-Immunology and AllergyiCCA intrahepatic cholangiocarcinomaCOVID-19 coronavirus disease 2019Liver Cancer Outcome in the COVID-19-pandemic ProjectSettore MED/12 - Gastroenterologiaddc:617IQRGastroenterologyBCLC Barcelona Clinic Liver Cancer:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]:neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas [ENFERMEDADES]Diseases of the digestive system. GastroenterologyManagementClinical PracticeClinical trialEuropean Network for the Study of Cholangiocarcinoma:Diagnosis::Clinical Decision-Making [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Fetge - Malalties - DiagnòsticInterquartile rangeLiver cancerLiver cancerPROGRESSION-FREE SURVIVALLiver Cancermedicine.medical_specialtyCoronavirus disease 2019 (COVID-19):Otros calificadores::/diagnóstico [Otros calificadores]610 Medicine & health:Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms [DISEASES]LT liver transplantationArticleBarcelona Clinic Liver CancerInternal MedicinemedicineENS-CCA European Network for the Study of CholangiocarcinomaHepatologybusiness.industryCERO-19 Liver Cancer Outcome in the COVID-19-pandemic ProjectCOVID-19IQR Interquartile rangemedicine.diseaseBCLCClinical trialEmergency medicineObservational study610 Medizin und GesundheitbusinessHCC hepatocellular carcinomaLC liver cancerSARS-CoV-2 severe acute respiratory syndrome coronavirus-2
researchProduct

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

2021

Valentina Burgio,1 Massimo Iavarone,2 Giovanni Giuseppe Di Costanzo,3 Fabio Marra,4 Sara Lonardi,5,6 Emiliano Tamburini,7 Fabio Piscaglia,8 Gianluca Masi,9,10 Ciro Celsa,11 Francesco Giuseppe Foschi,12 Marianna Silletta,13 Daniela Caterina Amoruso,14 Margherita Rimini,15 Mariangela Bruccoleri,2 Raffaella Tortora,3 Claudia Campani,4 Caterina Soldà,6 Massimo Giuseppe Viola,16 Antonella Forgione,8 Fabio Conti,12 Francesca Salani,9,10 Silvia Catanese,9,10 Carmelo Marco Giacchetto,17 Claudia Fulgenzi,13 Carmine Coppola,14 Pietro Lampertico,18 Antonio Pellino,6,19 Gabriele Rancatore,17 Giuseppe Cabibbo,17 Francesca Ratti,20 Federica Pedica,21 Angelo Della Corte,22 Massimo Colombo,18 Francesco De…

Oncologysorafenib.Cancer Management and ResearchhepatocarcinomaNeoplasms. Tumors. Oncology. Including cancer and carcinogenssorafeniblenvatinibneoplasmsdigestive system diseasesRC254-282Original ResearchCancer Management and Research
researchProduct

Refining sorafenib therapy: lessons from clinical practice

2015

ABSTRACT  Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. Based on Phase III and noninterventional study data, as well as our extensive experience, we discuss dose modification in order to manage adverse events, disease response evaluation and how to maximize treatment benefit. Sorafenib should be initiated at the approved dose (400 mg twice daily) and reduced/interrupted as appropriate in order to manage adverse events. Dose modification should be considered before discontinuation. Appropriate tumor response assessment is critical. Focusing on radiologic response may result in premature sorafenib discontinuation; symp…

Cancer ResearchSettore SECS-P/06 - Economia ApplicataAntineoplastic AgentAge FactorChild–Pugh Bpostprogression treatmentresponse assessmentdose modificationClinical Trials as TopicLiver Neoplasmsadverse event managementAge FactorsChild-Pugh Bpostprogression treatmenthepatocellular carcinomaGeneral MedicinePrognosisadverse event management; child–Pugh B; dose modification; elderly hepatocellular carcinoma; mRECIST; postprogression treatment; eal-world data; response assessment; sorafenibelderly hepatocellular carcinomaCombined Modality Therapychild–Pugh BClinical PracticeTreatment OutcomeOncologyLiver Neoplasmeal-world dataHepatocellular carcinomaadverse event managementRetreatmentDisease Progressiondose modificationHumanmedicine.drugPhenylurea CompoundNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularDisease ResponsePrognosielderly hepatocellular carcinomaProtein Kinase InhibitorAntineoplastic AgentsmRECISTelderlymRECISTAdverse event management Child–Pugh B dose modification elderly hepatocellular carcinoma mRECIST postprogression treatment real-world data response assessment sorafenibmedicineChild–Pugh BHumansCombined Modality TherapyIntensive care medicineAdverse effectProtein Kinase InhibitorsDose Modificationreal-world databusiness.industryPhenylurea Compoundsmedicine.diseaseDiscontinuationSurgeryreal-world dataresponse assessmentsorafenibbusinessFuture Oncology
researchProduct

International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis

2020

Background & Aims: Information on safety and efficacy of systemic treatment in patients with hepatocellular carcinoma (HCC) under dialysis are limited due to patient exclusion from clinical trials. Thus, we aimed to evaluate the rate, prevalence, tolerability, and outcome of sorafenib in this population. Methods: We report a multicenter study comprising patients from Latin America and Europe. Patients treated with sorafenib were enrolled; demographics, dose modifications, adverse events (AEs), treatment duration, and outcome of patients undergoing dialysis were recorded. Results: As of March 2018, 6156 HCC patients were treated in 44 centres and 22 patients were concomitantly under dial…

NiacinamidesafetySorafenibdialysimedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomamedicine.medical_treatmentPopulationadverse eventAntineoplastic Agentssurvival03 medical and health sciences0302 clinical medicineRenal DialysisInterquartile rangeInternal medicineHepatocellular carcinoma; adverse events; dialysis; safety; sorafenib; survivalmedicineHumanseducationDialysisAgededucation.field_of_studyHepatologybusiness.industryPhenylurea CompoundsLiver NeoplasmsRetrospective cohort studyHepatitis CSorafenibmedicine.diseaseadverse eventsEuropeTreatment OutcomeTolerability030220 oncology & carcinogenesisHepatocellular carcinomadialysissorafenib030211 gastroenterology & hepatologybusinessmedicine.drugLiver International
researchProduct

Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis

2018

Although studies suggest decreased incident hepatocellular carcinoma (HCC) after treatment with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, data are conflicting regarding risk and aggressiveness of recurrence in patients who have a history of treated HCC. This review analyses data available in literature in order to elucidate the impact of DAAs on the risk of HCC recurrence after successful treatment of the tumor. Overall 24 papers were identified. The available data cannot be considered definitive, but the initial alarmist data indicating an increased risk of recurrence have not been confirmed by most subsequent studies. The suggested aggressive pattern (rapid gr…

OncologyLiver CirrhosisCirrhosisSustained Virologic ResponseDAA; HCC; HCV; Recurrencemedicine.disease_causelaw.invention0302 clinical medicineRandomized controlled triallawDAA; HCC; HCV; Recurrence; Antiviral Agents; Carcinoma Hepatocellular; Disease Progression; Hepatitis C Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Recurrence Local; Neoplasm Staging; Risk Assessment; Sustained Virologic ResponseRecurrenceHCCChronicLiver NeoplasmsGastroenterologyhepatocellular carcinomaHepatitis CLocalDAA; HCC; HCV; Recurrence; Hepatology; Gastroenterology030220 oncology & carcinogenesisHepatocellular carcinomaHCVDisease Progression030211 gastroenterology & hepatologyRisk assessmentDirect actingRisk analysismedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusAntiviral AgentsRisk AssessmentDAA HCC HCV Recurrence03 medical and health sciencesInternal medicinemedicineHumansAntiviral treatmentDAANeoplasm StagingHepatologybusiness.industryCarcinomaHepatocellularHepatitis C Chronicmedicine.diseaseSettore MED/18 - Chirurgia GeneraleNeoplasm RecurrenceNeoplasm Recurrence Localbusiness
researchProduct